Charge-altering nucleic acid transporters with beta-amido carbonate backbones

A compound Formula (I):

• wherein:
• A is a substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocycloalkyl, substituted or unsubstituted C6-C10 aryl, or substituted or unsubstituted 5 to 10 membered heteroaryl;
• or
• A is a ligand moiety that binds to and is internalized by a cell surface receptor, optionally a saccharide, a disaccharide, an oligosaccharide, a liposaccharide, a lipid, a peptide, an antibody, or a small molecule;
• R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
• L1 and L2 are optional and each is independently a bond, —C(O)O—, —O—, —S—, —NH—, —C(O)NH—, —NHC(O)—, —S(O)2—, —S(O)NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
• LP1 and LP2 are each independently a functionalized beta-amido carbonate (bAC) monomer unit having a structure defined by
• wherein
• R2 is branched or unbranched, substituted or unsubstituted C8-C30 alkyl or heteroalkyl, which may be fully saturated, mono- or polyunsaturated;
• IM is an alpha aminoester monomer unit having a structure defined by
• where R3 is dihydrogen or methyl and R4 is dihydrogen or substituted or unsubstituted C2-C5 heteroalkyl, wherein the heteroatom is nitrogen and wherein the substituent, if present, is carbonyl;
• and
• z1 and z2 are independently 0 to 100, optionally from 5-20, and at least one of z1 or z2 is not 0;
• z3 is 2-100, optionally 5-20;
• and
• z4 is 1-100.